Setting	Value
Angle Weight	100
Max Jump Distance	80
Max Jump D to Split	80
Min Jump Distance	10000
Center Dampening	0
Angle Dampening	0.5
Max Area Delete	200
Min Area Ignore	20000
Max Penalty Merge	5000
Lower Thresh	1
Max Clusters Per Blob	1
Max Blobs to Detect	2
Max Sequence Length	120 or 180 (frame rate)
Max Penalty Merge	5000
Max Pred Error Increase	5000

Table S1. Tracking settings for motion, observation, and hindsight in Ctrax: The CaltechMultiple Fly Tracker.

	wildtype untreated		wildtype untreated
CTBP2 Puncta	<i>myo7aa<sup>./-</sup></i> untreated	MAGUK Puncta	<i>myo7aa<sup>-/-</sup></i> untreated
1	0.61	1	0.32
2	0.05	2	0.85
3	0.02	3	0.16
4	0.34	4	0.15
5	0.46	5	0.93
6+	0.07	6+	0.16

Table S2. *myo7aa*<sup>-/-</sup> have a statistically different distribution of CTBP2 puncta in the ribbon containing cells, but a similar distribution of MAGUK puncta in the post-synaptic densities. A t-test was used to determine statistical significance between wildtype and the *myo7aa*<sup>-/-</sup> mutant distribution of CTBP2 and MAGUK puncta. P-values are represented in each cell.

Α		wildtype untreated	
CTBP2	wildtype	wildtype	wildtype
Puncta	5 µM (±)-Bay K 8644	250 µM Nefiracetam	125 µM (R)-Baclofen
1	0.0003	0.64	0.61
2	<0.0001	0.13	0.01
3	0.04	0.30	0.25
4	0.03	0.13	0.56
5	0.07	0.87	0.13
6+	0.18	0.38	0.04

В		<i>myo7aa<sup>≁</sup></i> untreated	
CTBP2 Puncta	<i>myo7aa<sup>-/-</sup></i> 5 µM (±)-Bay K 8644	<i>myo7aa<sup>-/-</sup></i> 250 µM Nefiracetam	<i>myo7aa<sup>∽</sup></i> 125 µM (R)-Baclofen
1	0.06	0.23	0.28
2	0.27	0.34	0.22
3	0.036	0.048	0.025
4	0.27	0.66	0.22
5	0.09	0.17	0.11
6+	0.63	0.57	0.74

Table S3. L-type voltage-gated calcium channel agonists change the distribution of CTBP2 puncta in *myo7aa*<sup>-/-</sup> mutant ribbon containing cells. Table A represents the statistical analysis for all wildtype treated animals compared to untreated wildtype animals for each number of puncta. (±)-Bay K 8644 had the largest effect on wildtype ribbon containing cells. Table B represents statistical analysis for all *myo7aa*<sup>-/-</sup> treated animals compared to untreated *myo7aa*<sup>-/-</sup> animals for each number of puncta. All three L-type voltage-gated calcium channel agonists had a statistical significance at 3 puncta. A t-test was used to determine statistical significance between treated and untreated groups. P-values are represented in each cell.

Α		wildtype untreated	
MAGUK Puncta	wildtype 5 μM (±)-Bay K 8644	wildtype 250 µM Nefiracetam	wildtype 125 µM (R)-Baclofen
1	0.22	0.08	0.79
2	0.10	0.10	0.36
3	0.98	0.92	0.37
4	0.03	0.64	0.12
5	0.31	0.99	0.44
6+	0.67	0.60	0.08

В		<i>myo7aa</i> <sup>-/-</sup> untreated	
MAGUK Puncta	<i>myo7aa<sup>-/-</sup></i> 5 µM (±)-Bay K 8644	<i>myo7aa<sup>-/-</sup></i> 250 µM Nefiracetam	<i>myo7aa<sup>-/-</sup></i> 125 µM (R)-Baclofen
1	0.83	0.74	0.45
2	0.32	0.68	0.26
3	0.46	0.64	0.40
4	0.65	0.66	0.61
5	0.98	0.78	0.33
6+	0.61	0.79	0.29

Table S4. L-type voltage-gated calcium channel agonists do not change the distribution of MAGUK puncta in *myo7aa*<sup>-/-</sup> mutant post-synaptic densities. Table A represents statistical analysis for all wildtype treated animals compared to untreated wildtype animals for each number of puncta. There was no change in the distribution of MAGUK puncta, except at 4 puncta upon incubation with 5  $\mu$ M (±)-Bay K 8644. Table B represents statistical analysis for all *myo7aa*<sup>-/-</sup> treated animals compared to untreated *myo7aa*<sup>-/-</sup> animals for each number of puncta. All three L-type voltage-gated calcium channel agonists had no effect on the number of MAGUK puncta in the post-synaptic densities. A t-test was used to determine statistical significance between treated and untreated groups. P-values are represented in each cell.

Α		wildtype untreated	
Frequency (Hz)	wildtype 5 μΜ (±)-Bay K 8644	wildtype 250 µM Nefiracetam	wildtype 125 µM (R)-Baclofen
200	0.34	0.0001	<0.0001
300	0.0009	0.003	<0.0001
400	0.04	0.01	<0.0001
500	<0.0001	0.03	<0.0001
600	0.002	0.006	0.0004
В		<i>myo7aa<sup>-/-</sup></i> untreated	
Frequency (Hz)	<i>my</i> o7aa <sup>-/-</sup> 5 μΜ (±)-Bay K 8644	<i>myo7aa<sup>-⊱</sup></i> 250 µM Nefiracetam	<i>myo7aa<sup>-/-</sup></i> 125 µM (R)-Baclofen
200	<0.0001	0.016	1.0
300	0.006	1.0	1.0
400	<0.0001	0.008	1.0
500	0.006	0.08	1.0
600	<0.0001	0.14	0.51

Table S5. (±)-Bay K 8644 produces the most robust improvement in acoustic startle response in *myo7aa*<sup>-/-</sup> mutants. Table A represents statistical analysis for all wildtype treated animals compared to untreated wildtype animals for each frequency. Table B represents statistical analysis for all *myo7aa*<sup>-/-</sup> mutants treated compared to untreated *myo7aa*<sup>-/-</sup> mutants for each frequency. A two-tailed Fisher's exact test was used to determine statistical significance between untreated and treated group. P-values are represented in each cell.







Fig. S1. Wildtype ribbon synapses unaffected with exposure to L-type voltage-gated calcium channel agonists. (A-D) Representative images of 5 dpf wildtype untreated and treated with 5  $\mu$ M (±)-Bay K 8644 (B), 250  $\mu$ M Nefiracetam (C) and 125  $\mu$ M (R)-Baclofen (D) ribbon synapse structure obtained with transmission electron microscopy. Scale bars: 200 nm. (E) Wildtype treated and untreated ribbon synapse areas are comparable. (F) Additionally, untreated and treated wildtype ribbons have a comparable number of tethered vesicles. Black bold line represents the mean of the data set and error bars are 95% confidence intervals. Experiments were replicated two times for wildtype animals incubated in 5  $\mu$ M (±)-Bay K 8644, four times for animals incubated in 250  $\mu$ M Nefiracetam and three times for animals incubated in 125  $\mu$ M (R)-Baclofen.







**Fig. S3 (±)-Bay K 8644 increases total number of post-synaptic densities per neuromast and total number of MAGUK puncta per neuromast in the** *myo7aa*<sup>-/-</sup> **mutants.** (A) 5 dpf wildtype neuromasts treated with (±)-Bay K 8644 have a greater number of post-synaptic densities and those treated with (R)-Baclofen have an increase in both the number of postsynaptic densities and total number of MAGUK puncta compared to untreated wildtype neuromasts (t-test). (B) 5 dpf *myo7aa*<sup>-/-</sup> neuromasts treated with (±)-Bay K 8644 have a greater number of post-synaptic densities and total number of MAGUK puncta compared to untreated *myo7aa*<sup>-/-</sup> neuromasts (t-test). Black bold line represents the mean of the data set and error bars are 95% confidence intervals.






Fig. S4 Different doses of Nefiracetam have different effects on wildtype and *myo7aa*<sup>-/-</sup> **mutant swimming behavior.** This behavior assessment tracks movement of 5 dpf wildtype and *myo7aa*<sup>-/-</sup> larvae over a 2.5 minute interval with a 5 ms electric stimulus (50 mV) administered every 20 s. Ctrax software was used for video processing and Matlab 2012b for video analysis. (A, B) Incubation with 85  $\mu$ M and 250  $\mu$ M Nefiracetam had no adverse effects on wildtype swimming behavior; however incubation with 125  $\mu$ M increased the absolute smooth orientation (turning angle as a function of time) of wildtype larvae. Incubation with 85  $\mu$ M and 125  $\mu$ M Nefiracetam had no effect on *myo7aa*<sup>-/-</sup> larvae but incubation with 250  $\mu$ M did decrease the absolute smooth orientations compared to those untreated. Individual turning angles from populations of wildtype and *myo7aa*<sup>-/-</sup> larvae treated and untreated were used to construct the lines (t-test). The black bold line represents the mean of the data set and error bars are 95% confidence intervals. These experiments were replicated twice for each dose for each genotype.











Fig. S6 Different doses of (R)-Baclofen have different effects on wildtype and *myo7aa*<sup>-/-</sup> mutant swimming behavior. (A, B) Incubation with 125  $\mu$ M and 1 mM (R)-Baclofen had no adverse effects on wildtype swimming behavior; however incubation with 75  $\mu$ M, 250  $\mu$ M and 500  $\mu$ M increased the absolute smooth orientation (turning angle as a function of time) of wildtype larvae. Incubation with all 5 doses of (R)-Baclofen did decrease the absolute smooth orientations of *myo7aa*<sup>-/-</sup> mutants compared to those untreated. Individual turning angles from populations of wildtype and *myo7aa*<sup>-/-</sup> larvae treated and untreated were used to construct the lines (t-test). The black bold line represents the mean of the data set and error bars are 95% confidence intervals. These experiments were replicated twice for each dose for each genotype.







**Fig. S8 250 μM Nefiracetam and 125 μM (R)-Baclofen have no effect on inflation of swim bladder on both wildtype and** *myo7aa*<sup>-/-</sup> **larvae.** (A, B, C) At 5 dpf wildtype fish swim bladder inflation is unaffected upon incubation with either compound. (D, E, F) At 5 dpf *myo7aa*<sup>-/-</sup> mutant swim bladder inflation is unaffected upon incubation with either 250 μM Nefiracetam or 125 μM (R)-Baclofen. These experiments were replicated twice for each dose for each genotype.